Monday, September 14, 2026

Trump’s $350 Billion Investment Deal: What Does It Mean for Korea and Japan?

Trump claims South Korea will invest $350 billion in the U.S., but discrepancies in agreements raise questions about accuracy.

Trump vs. Pope Leo XIV: Will Political Tensions Shape the Upcoming U.S. Midterms?

Trump faces backlash from Pope Leo XIV over the Iran war, risking political fallout ahead of the midterm elections.

Kolon Group’s Biotech Bet Faces Uncertainty as October Trial Readout Becomes Critical

Kolon TissueGene's TG-C osteoarthritis treatment failed its first U.S. Phase 3 trial, raising doubts about the biotech's future.

Tag: HLB

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Revolutionary Liver Cancer Treatment: How Rivoceranib + Camrelizumab Outperforms Sorafenib in Young Patients

HLB's liver cancer drug combo shows consistent efficacy across all age groups.

HLB’s Rivoceranib Drug Approval: What the FDA’s VAI Classification Means for Liver Cancer Treatment

HLB's Rivoceranib facility received a VAI classification from the FDA, indicating compliance with GMP standards, aiding drug approval progress.

HLB’s Liver Cancer Drug: FDA’s VAI Conclusion Sparks Hope for Approval

HLB's Rivoceranib facility passed FDA inspection, receiving VAI classification, moving towards new liver cancer drug approval.

[Exclusive] HLB’s Liver Cancer Drug Clears Camrelizumab CMC Review, but Hengrui Manufacturing Facility Becomes New Hurdle

HLB's liver cancer drug approval faces delays due to FDA findings at Hengrui's facility, despite resolution of previous issues.

GF Fermentech Showcases Synthetic Biology CDMO Platform at SynBioBeta 2026

GF Fermentech showcased its CDMO platform at SynBioBeta 2026, emphasizing rapid commercialization and advanced production technologies.

HLB Life Science R&D: Leading the Charge in CBD Pharmaceutical Development in 2026

HLB Life Science R&D partners for a national project to develop medical cannabis-based pharmaceuticals, focusing on CBD production.

Unlock Radiant Skin: LABSENN’s Calming Serum Offers Powerful Anti-Aging Benefits

HLB Peptide launches LABSENN, a derma-science brand featuring innovative peptide technology and the Peptide Calming Serum for sensitive skin.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.